Stephen Ejeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen Ejeh has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Adamu Uzairu
10 shared publications- Gideon Adamu Shallangwa
Ahmadu Bello University
7 shared publications Stephen E. Abechi
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria, Kaduna, Nigeria
7 shared publicationsMuhammad Tukur Ibrahim
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria Kaduna, Nigeria
6 shared publicationsRamith Ramu
Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysore, India
4 shared publicationsAbduljelil Ajala
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria Kaduna, Nigeria
3 shared publications
Latest Publications
- 3 October 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 1-15
Computer-aided design process of possible antisickling agents using molecular docking, pharmacokinetic assessment, homology modeling, and molecular dynamic studies targeting Hba protein
Sickle cell disease (SCD), a multiorgan disease that is one of the most common genetic ailments, affects about 15 million people globally. The findings for drugs that bind to hemoglobin and adjust the oxygenation condition have been a key component of SCD treatment. The goal of this study was to use computational methods to find lead compounds, design novel bioactive molecules that are strong SCD inhibitors, and gain further knowledge about their reaction process. With data demonstrating predictive properties of R2 = 0.990, \(\:{R}_{pred}^{2}\) = 0.980, and \(\:{Q}_{CV}^{2}\) = 0.987, the developed QSAR model is statistically reliable and highly predictive. It also satisfies the established standards for sound models, which are recommended by numerous institutions. According to the study, the designed molecules (DM) exhibit predicted biological activity (pIC50) of 6.843, 6.671, and 6.912 in comparison to pIC50 of 5.403 for the TM and 4.956 for the SD. Additionally, molecules DM1, DM2, and DM3 exhibit better drug ratings of 0.67, 0.56, and 0.91, respectively, compared to drug scores of 0.44 for TM and 0.49 for SD, suggesting better pharmacokinetic properties than TM and SD. The protein-DM3 complex showed higher binding free energies than the protein-L-glutamate complex, indicating that it is more stable, according to MD simulation, which was used to determine the stability of the proposed molecule.- 3 October 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 1-15
Computer-aided design process of possible antisickling agents using molecular docking, pharmacokinetic assessment, homology modeling, and molecular dynamic studies targeting Hba protein
Sickle cell disease (SCD), a multiorgan disease that is one of the most common genetic ailments, affects about 15 million people globally. The findings for drugs that bind to hemoglobin and adjust the oxygenation condition have been a key component of SCD treatment. The goal of this study was to use computational methods to find lead compounds, design novel bioactive molecules that are strong SCD inhibitors, and gain further knowledge about their reaction process. With data demonstrating predictive properties of R2 = 0.990, \(\:{R}_{pred}^{2}\) = 0.980, and \(\:{Q}_{CV}^{2}\) = 0.987, the developed QSAR model is statistically reliable and highly predictive. It also satisfies the established standards for sound models, which are recommended by numerous institutions. According to the study, the designed molecules (DM) exhibit predicted biological activity (pIC50) of 6.843, 6.671, and 6.912 in comparison to pIC50 of 5.403 for the TM and 4.956 for the SD. Additionally, molecules DM1, DM2, and DM3 exhibit better drug ratings of 0.67, 0.56, and 0.91, respectively, compared to drug scores of 0.44 for TM and 0.49 for SD, suggesting better pharmacokinetic properties than TM and SD. The protein-DM3 complex showed higher binding free energies than the protein-L-glutamate complex, indicating that it is more stable, according to MD simulation, which was used to determine the stability of the proposed molecule.- Open Access
- 18 June 2025
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 1
Computational techniques for analyzing and interpreting some quinoxaline-containing molecules as possible anti-schistosomal agents using docking, pharmacokinetics, drug-likeness, QSAR, and molecular dynamics evaluation
- 18 June 2025
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 1
Open AccessComputational techniques for analyzing and interpreting some quinoxaline-containing molecules as possible anti-schistosomal agents using docking, pharmacokinetics, drug-likeness, QSAR, and molecular dynamics evaluation
- Open Access
- 23 March 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-14
In-silico screening, pharmacokinetic evaluation, DFT study, and molecular dynamic simulation as approaches for the identification of acetamide and acetic acid derivatives as potential antisickling agents targeting Hba protein
- 23 March 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-14
Open AccessIn-silico screening, pharmacokinetic evaluation, DFT study, and molecular dynamic simulation as approaches for the identification of acetamide and acetic acid derivatives as potential antisickling agents targeting Hba protein
- Open Access
- 1 August 2024
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 2 (4) , 554-564
In-silico screening and ADMET evaluation of therapeutic MAO-B inhibitors against Parkinson disease
- 1 August 2024
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 2 (4) , 554-564
Open AccessIn-silico screening and ADMET evaluation of therapeutic MAO-B inhibitors against Parkinson disease
- Open Access
- 18 January 2024
- Published by Elsevier in Scientific African
- Vol. 23
In silico screening, pharmacokinetic, DFT, and dynamics simulation study of ant-hepatitis C virus compounds as potential NS5B Polymerase inhibitors
- 18 January 2024
- Published by Elsevier in Scientific African
- Vol. 23
Open AccessIn silico screening, pharmacokinetic, DFT, and dynamics simulation study of ant-hepatitis C virus compounds as potential NS5B Polymerase inhibitors
- Top Cited Papers
- 1 January 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1302
Computational evaluation of the inhibitory potential of some urea, thiourea, and selenourea derivatives of diselenides against leishmaniasis: 2D-QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation
- 1 January 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1302
Top Cited PapersComputational evaluation of the inhibitory potential of some urea, thiourea, and selenourea derivatives of diselenides against leishmaniasis: 2D-QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation
- Open Access
- 4 August 2023
- Published by Elsevier in Scientific African
- Vol. 21
In silico screening of potential Tumor necrosis factor alpha (TNF-α) inhibitors through molecular modeling, molecular docking, and pharmacokinetics evaluations
- 4 August 2023
- Published by Elsevier in Scientific African
- Vol. 21
Open AccessIn silico screening of potential Tumor necrosis factor alpha (TNF-α) inhibitors through molecular modeling, molecular docking, and pharmacokinetics evaluations
- Open Access
- 13 March 2023
- Published by Taylor & Francis in Egyptian Journal of Basic and Applied Sciences
- Vol. 10 (1) , 240-254
Pharmacoinformatics-based strategy in designing and profiling of some Pyrazole analogues as novel hepatitis C virus inhibitors with pharmacokinetic analysis
Hepatitis C virus (HCV) infection promotes death rates all over the world. Sofosbuvir is a standard drug for the cure of HCV but unfortunately, it receives a lot of attention for its pricing problems. As a result, it is crucial to consider alternative HCV treatments that are both cost-effective and free of side effects. We report how a pharmacoinformatics-based technique was used to generate and profile certain Pyrazole analogues as novel hepatitis C virus inhibitors by exploring the PubChem drug repository for the lead molecule with further optimization. The proposed molecules all interact by filling the protein target’s binding domain to inhibit the receptor. With binding energy of −35.72 kcal/mol, compound 17e was found as a highly potent NS5B inhibitor, exceeding Sofosbuvir, the FDA-approved NS5B inhibitor with a binding energy of −30.34 kcal/mol. Additionally, the ADMET assessment of the selected molecules (17e) shows outstanding quality with a drug score of 0.74 when especially in comparison to Sofosbuvir, which has a drug score of 0.31. Future studies should therefore focus on the molecular dynamics, synthesis, in vivo testing, and in vitro evaluation of these substances to validate our hypothesis.
- 13 March 2023
- Published by Taylor & Francis in Egyptian Journal of Basic and Applied Sciences
- Vol. 10 (1) , 240-254
Open AccessPharmacoinformatics-based strategy in designing and profiling of some Pyrazole analogues as novel hepatitis C virus inhibitors with pharmacokinetic analysis
Hepatitis C virus (HCV) infection promotes death rates all over the world. Sofosbuvir is a standard drug for the cure of HCV but unfortunately, it receives a lot of attention for its pricing problems. As a result, it is crucial to consider alternative HCV treatments that are both cost-effective and free of side effects. We report how a pharmacoinformatics-based technique was used to generate and profile certain Pyrazole analogues as novel hepatitis C virus inhibitors by exploring the PubChem drug repository for the lead molecule with further optimization. The proposed molecules all interact by filling the protein target’s binding domain to inhibit the receptor. With binding energy of −35.72 kcal/mol, compound 17e was found as a highly potent NS5B inhibitor, exceeding Sofosbuvir, the FDA-approved NS5B inhibitor with a binding energy of −30.34 kcal/mol. Additionally, the ADMET assessment of the selected molecules (17e) shows outstanding quality with a drug score of 0.74 when especially in comparison to Sofosbuvir, which has a drug score of 0.31. Future studies should therefore focus on the molecular dynamics, synthesis, in vivo testing, and in vitro evaluation of these substances to validate our hypothesis.